Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00076063 · ClinicalTrials.gov registry record · Phase 1

A Study of LIPO-5 and ALVAC-HIV (vCP1452) as Possible HIV Vaccines

A Phase 1 study of HIV Infections, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).

Completed
Registry status
Phase 1
Development phase
174
Enrollment target
11
Study locations

NCT00076063 is a Phase 1 study of HIV Infections that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 174 participants, below the 446-participant average among 542 other HIV Infections trials with a reported enrollment target (61% lower). The trial reports 11 study locations across 8 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00076063, a Phase 1 study of HIV Infections, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).

COMPLETED
Registry status
Phase 1
Development phase
174 participants
Enrollment target
11
Study locations

Study Summary

This study will test the immune system response to and safety of two HIV vaccines alone and in combination: ALVAC-HIV (vCP1452) and LIPO-5. ALVAC-HIV (vCP1452) uses a canarypox virus with man-made parts of HIV attached to it. The canarypox virus cannot cause disease in people. LIPO-5 is a mixture of five man-made proteins similar to proteins found in HIV. These vaccines are not produced from live HIV or from infected cells and do not contain the virus. It is not possible to become infected with HIV from these vaccines.

Conditions Studied

HIV Infections

Interventions

  • BIOLOGICAL ALVAC-HIV (vCP1452)
  • BIOLOGICAL LIPO-5

Study Locations (11)

Maryland

  • Johns Hopkins Bloomberg School of Public Health,Ctr for Immunization Research,Project SAVE-Baltimore - Baltimore
  • Project Brave HIV Vaccine CRS - Baltimore

Massachusetts

  • Brigham and Women's Hosp. CRS - Boston
  • Fenway Community Health Clinical Research Site (FCHCRS) - Boston

New York

  • Univ. of Rochester HVTN CRS - Rochester
  • NY Blood Ctr./Bronx CRS - The Bronx

Alabama

  • Alabama Vaccine CRS - Birmingham

Missouri

  • Saint Louis Univ. School of Medicine, HVTU - St Louis

Rhode Island

  • Miriam Hospital's HVTU - Providence

Tennessee

  • Vanderbilt Vaccine CRS - Nashville

Washington

  • FHCRC/UW Vaccine CRS - Seattle

Trial Details

FieldValue
Enrollment Target 174 participants
Start Date 2004-03
Est. Completion 2007-03
Phase Phase 1

Sponsor

National Institute of Allergy and Infectious Diseases (NIAID)

2,006 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00076063

The ClinicalTrials.gov registry entry for NCT00076063 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 174 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 446-participant average among 542 other HIV Infections trials with a reported enrollment target (61% lower). The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with HIV Infections appearing as the primary indexed condition, and to 2 interventions - of which ALVAC-HIV (vCP1452) is the first listed.

NCT00076063 reports 11 study locations spanning 8 distinct geographic areas - top geographies include Maryland, Massachusetts, New York.

Frequently Asked Questions

What is clinical trial NCT00076063 about?

NCT00076063 is a clinical study titled "A Study of LIPO-5 and ALVAC-HIV (vCP1452) as Possible HIV Vaccines". This study will test the immune system response to and safety of two HIV vaccines alone and in combination: ALVAC-HIV (vCP1452) and LIPO-5. ALVAC-HIV (vCP1452) uses a canarypox virus with man-made parts of HIV attached to it. The canarypox virus cannot cause disease in people. LIPO-5 is a mixture of...

What is the current status of trial NCT00076063?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 174 participants. The study started on 2004-03. Estimated completion is 2007-03.

What conditions does trial NCT00076063 study?

This clinical trial studies the following conditions: HIV Infections.

What interventions are being tested in trial NCT00076063?

The interventions under investigation include: ALVAC-HIV (vCP1452) (BIOLOGICAL), LIPO-5 (BIOLOGICAL).

Who is sponsoring clinical trial NCT00076063?

This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00076063 being conducted?

This trial has 11 study locations across Alabama, Maryland, Massachusetts, Missouri, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for HIV Infections

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

HIV Infections

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.